The Alzheimer’s Impact Movement (AIM) engages with corporate partners on various projects including advocate training, health economics, legal issues surrounding a diagnosis and public opinion polling.

No contribution from any entity impacts AIM decision-making, nor our positions on issues related to people living with Alzheimer’s, other dementia and their families. Total contributions from the pharmaceutical industry makes 1.13% of AIM’s total contributed revenue.